After a prolonged dearth of favorable news about blood substitutes, corporate persistence is building toward the next threshold of product development events.
Last week's announcement by Alliance Pharmaceutical Corp. that it signed an exclusive licensing agreement with Johnson & Johnson's Ortho Biotech Inc. makes it the second blood substitute company this year to partner with a pharmaceutical company that will take on the substantial costs of late-stage development of the products.
The license covers injectable perfluorochemical emulsions capable of transporting oxygen for all medical uses. Under the agreement, the R.W. Johnson Pharmaceutical Research Institute and ALLP will develop Oxygent as a temporary blood substitute. Ortho will market the product after funding all remaining Phase II and III trials.
Oxygent is in Phase II studies in surgical patients at three undisclosed therapeutic doses. The study is slated to end late this